Introduction
============

Childhood acute lymphoblastic leukemia (ALL) patients may experience immunosuppression, either due to the disease or as a result of chemotherapy, or both. This condition occurs particularly during induction and re-induction phases, in which intensive treatment is conducted.[@b1-jbm-4-001]--[@b3-jbm-4-001] It may lead to fatal infections, especially if the patients are malnourished and if there is lack of access to supportive care. Previous studies have shown that prophylactic antimicrobial treatment can reduce infection-related morbidity and mortality after oral or intravenous administration.[@b4-jbm-4-001]--[@b9-jbm-4-001]

Contrary to the setting in high-income countries, poverty, malnutrition, and the generally poor clinical condition of patients, as well as poor access to supportive care in low- to middle-income countries, have generated a higher incidence of treatment-related mortality and lower remission rates. A study in Dr Sardjito Hospital, Yogyakarta, Indonesia, as reported by Mostert et al,[@b10-jbm-4-001] revealed that between 1997 and 2002 the toxic death rate was an obvious problem; approximately 23% of patients experienced treatment-related death and 35% refused or abandoned treatment. The majority of these events occurred during induction. Both events result in low remission and cure rates in our hospital setting.

We therefore conducted this randomized, double-blind study to test the role of ciprofloxacin oral monotherapy as prophylaxis for bacterial infection and toxic death during induction treatment of Indonesian childhood ALL protocol.

Patients and methods
====================

Patients
--------

The study groups consisted of children with ALL hospitalized in Dr Sardjito Hospital, Yogyakarta, Indonesia from July 1999 until June 2005, who met the inclusion criteria as follows: diagnosis of ALL based on French--American--British morphology classification of L1 or L2;[@b11-jbm-4-001] and age between 0 and 14 completed years during induction treatment for the standard risk (SR) and high risk (HR) groups of the Indonesian Wijaya Kusuma (WK)-ALL-2000 protocol. Patients were defined as SR when their age at diagnosis was between 1 year and 9 completed years; their WBC count was less than 50 × 10^9^/L; and there was an absence of mediastinal mass and no signs of central nervous system (CNS) involvement. Patients who did not meet SR criteria were assigned as HR. SR patients with a day 8 absolute peripheral lymphoblasts count 1 × 10^9^/L or higher were upgraded to the HR group and treated accordingly. Fever was defined as an axillary temperature ≥ 38.5°C in a single determination or \>38°C after two measurements with a 1-hour interval between each measurement. Clinical sepsis was defined when there was fever plus documented clinical signs and symptoms of systemic infection with or without increasing C-reactive protein level. Microbiological studies and surveillance were not always done for financial reasons.

The exclusion criteria were known allergy to quinolones, epilepsy, and/or body weight (BW) less than 10 kg. Patients were classified as undernourished at diagnosis when Z-score value was -2 SD or less based on weight-for-age (0--5 years) and height-for-age (5--15 years) World Health Organization standards for nutritional status.[@b12-jbm-4-001],[@b13-jbm-4-001]

The WK-ALL-2000 protocol
------------------------

The WK-ALL-2000 protocol for childhood ALL was developed in 1998--1999 as a relatively economical, reduced-intensity protocol to meet conditions in Indonesia after the Asian economical crisis.[@b14-jbm-4-001] The protocol includes a 6-week induction treatment of three doses of weekly age-adjusted intrathecal methotrexate administered in weeks 0, 2, and 6; daily oral dexamethasone 6 mg/m^2^ for 42 days; five doses of weekly intravenous vincristine 1.5 mg/m^2^ during weeks 1--5; and two doses of intravenous *Escherichia coli* L-asparaginase 6000 IU/m^2^ in weeks 1 and 2 for SR or weeks 4 and 5 for HR patients. One dose of intravenous daunorubicin 30 mg/m^2^ was added at week 1 for HR patients only. HR patients also received a re-induction schedule inserted between the consolidation and maintenance phase. The scheme of the protocol is shown in [Table 1](#t1-jbm-4-001){ref-type="table"}.

Random assignment
-----------------

Patients were randomized using a computer into arm A and arm B. Arm A had tablets containing ciprofloxacin prepared in the pharmacy, while the placebo tablet contained tasteless material. Both the patients and the doctors and other staff were blinded to the tablet contents, and the groups were not unblinded until after the inclusion period had ended.

The tablets were taken orally twice per day from the onset of chemotherapy administration. The ciprofloxacin doses depended on the patient's BW: BW 10--14 kg = 2 × 125 mg; BW 15--24 kg = 2 × 250 mg; BW 25--39 kg = 2 × 500 mg; and BW 40 kg or more = 2 × 750 mg. The tablets were taken continuously at home when the patient was discharged from hospital until completion of induction treatment. Modification of this treatment was permitted if the patient had fever.

Statistical analysis
====================

The data were collected in a research-patient file and transferred to a computer spreadsheet form containing information of the protocol used, presentation at diagnosis (sex, age group, WBC group, risk group, nutritional status), day 8 peripheral lymphoblasts count, any fever and clinical sepsis, date of death or abandonment, and remission status at the end of the induction treatment.

The protocol stated day 43 as the end of induction treatment and remission determination. Patients achieved complete remission when their lymphoblast count in bone marrow was less than 5% without any signs of leukemic infiltration in peripheral blood, cerebrospinal fluid, or other organs. Abandonment of treatment, death, and no remission achievement were classified as induction failures.

The outcomes measured in this study were fever, clinical sepsis and mortality. The analysis was carried out using SPSS software (v13; IBM Corporation, Armonk, NY) and statistical significance was defined at the two-sided *P-*value \< 0.05.

Results
=======

One-hundred and ten patients were enrolled in this study and randomized into arm A (58 patients or 53%) and arm B (52 patients or 47%). The characteristics of patients were not equally divided between the two groups as shown in [Table 2](#t2-jbm-4-001){ref-type="table"}. The ciprofloxacin group was less often under-nourished than the placebo group (24.1% vs 44.2%, *P* = 0.03).

Of the 110 patients, 79 (71.8%) achieved complete remission. Adverse outcomes during induction treatment were dominated by death (12.8%) and abandonment (9.0%). The remaining patients (6.4%) had resistant disease. Patients in the ciprofloxacin arm have a greater induction failure rate (31.0% vs 25.0%; 95% CI: 0.58--3.12; *P* = 0.48; [Table 3](#t3-jbm-4-001){ref-type="table"}), more fever (50.0% vs 32.7%; 95% CI: 0.95--4.47; *P* = 0.07), more clinical sepsis (50.0% vs 38.5%; 95% CI: 0.75--3.42; *P* = 0.22), and more toxic death (18.9% vs 5.8%; 95% CI: 0.92--13.80; *P* = 0.05). However, these results were not statistically significant. Twelve of 14 induction deaths occurred in the hospital; six of these were infective death, due to sepsis (five patients) and varicella (one patient) as shown in [Table 4](#t4-jbm-4-001){ref-type="table"}. However, the patients diagnosed with disseminated intravascular coagulation, multiorgan dysfunction syndrome, and shock may well have had infection as the causative event. The nadir of the absolute neutrophil count during induction in the ciprofloxacin arm was lower than in the placebo arm (median 62 \[range: 5--884\] vs 270 \[range: 14--25,480\] cells/μl; *P* \< 0.01). The ciprofloxacin arm and the placebo arm had an equal induction duration (median 43 \[range: 40--58\] vs 43 \[range: 39--59\] days, respectively).

[Table 5](#t5-jbm-4-001){ref-type="table"} shows that there was no significant difference in the incidence of diarrhea, nausea, vomiting, and neuritis as adverse events during induction between the ciprofloxacin arm and placebo arm. The characteristics and clinical outcome during induction treatment of each patient is shown in [Table 6](#t6-jbm-4-001){ref-type="table"}.

Discussion
==========

Deaths, whether related to the disease itself or chemotherapy-induced, are common in leukemia treatment. The toxic death rate (23%) together with treatment refusal or abandonment of treatment (35%) are big problems in Dr Sardjito Hospital.[@b10-jbm-4-001] These kinds of problems are typically found in resource-poor countries with poor and malnourished patients, poor access to supportive care, and lack of access to medicines.[@b15-jbm-4-001]--[@b17-jbm-4-001] The condition is contrary to that in high-income countries where toxic death rates are generally much fewer (2%--4%) and abandonment is virtually unknown.[@b18-jbm-4-001],[@b19-jbm-4-001] An important underlying cause of a high toxic death rate in childhood ALL is neutropenia, which may be found at diagnosis as a consequence of the leukemia itself, or following chemotherapy. Infections in individuals with neutropenia can develop into a life threatening condition and therefore require prompt intervention. Initiation of empiric antibiotics immediately after the neutropenic cancer patient becomes febrile has been the single most important advance in the management efforts to diminish mortality rates in the immunocompromized host.[@b20-jbm-4-001] Unfortunately, trials to decrease the infection-related mortality in neutropenic patients utilizing antibacterial prophylaxis and the use of hematopoietic growth-stimulating factors have shown conflicting results.[@b8-jbm-4-001],[@b21-jbm-4-001]--[@b24-jbm-4-001] In terms of primary antibiotic prophylaxis, ciprofloxacin or quinolone derivates have been widely used because they show wide antibacterial spectrum activity, mainly against Gram-negative bacteria from the gut, where invasive bacteria for systemic infection originate. Another benefit of quinolones, besides their effectiveness, is that they are generally well-tolerated and can be administered orally.[@b7-jbm-4-001],[@b25-jbm-4-001],[@b26-jbm-4-001] Based on such findings, and because it is available at low-cost in our setting, we used ciprofloxacin in our study. We hypothesized that prophylactic ciprofloxacin administration would diminish infection and mortality during induction, thus increasing the remission and cure rates of childhood ALL in our hospital setting.

Some unexpected results were obtained in our study. First of all, the randomization was not balanced for malnutrition, and the ciprofloxacin group had the lower percentage of malnourished patients. It is clear that malnutrition is an important factor for fever and infection; nevertheless, patients in the ciprofloxacin arm showed a higher risk of developing fever, clinical sepsis, and death from complications than patients in the placebo arm. Therefore, we checked whether the groups had not been accidentally exchanged, but this was not the case: the arm A tablets indeed contained ciprofloxacin, and those of arm B were placebo. The finding of more toxic death in the ciprofloxacin arm in our study was contrary to most previous studies, which have shown reduced events of fever, sepsis, or mortality.[@b6-jbm-4-001],[@b9-jbm-4-001],[@b27-jbm-4-001],[@b28-jbm-4-001] We did not ascertain a definite cause for this finding.

Side effects related to ciprofloxacin in our study were mild and manageable, limited to nausea or vomiting and diarrhea as reported in previous studies.[@b29-jbm-4-001],[@b30-jbm-4-001] Neutropenia or marrow suppression caused by ciprofloxacin is rare.[@b25-jbm-4-001] When we checked our database, however, we found that the ciprofloxacin group had a lower nadir of absolute neutrophil count. This may explain the higher incidence of fever, sepsis and death. It may moreover influence the gut flora or gut mucosa in a negative way, facilitating pathogens to invade into the circulation. We thought that the lower nadir of neutrophil count in the ciprofloxacin group may have been a predisposing factor to fever and infection, sepsis, and death in this study. It is reasonable to assume that patients who got sepsis were at greater risk of death.

Another jeopardizing impact of ciprofloxacin and fluoroquinolone is the emergence of resistant bacteria after its administration as prophylactic antibiotic,[@b31-jbm-4-001]--[@b36-jbm-4-001] but we could not find evidence for this because we were not able to conduct microbiological surveillance in this study. A further limitation was the bitter taste of ciprofloxacin, which might have influenced compliance to take the tablets when the patients were at home. High induction death rate in our study was related to the setting in Dr Sardjito Hospital, where childhood ALL patients were nursed in a general pediatric ward, and lack of supportive care. Occasionally, unavailability of medicines and late initiation of intravenous antibiotic therapy in neutropenic patients with fever also contributed to our high death rate. Due to lack of microbiological data, we could not show the cause of the infective deaths.

Conclusion
==========

The use of ciprofloxacin prophylaxis after chemotherapy in childhood ALL is not warranted in our setting. Further study is needed to determine the rational use of ciprofloxacin in low-income countries and to limit the risk of the occurrence of microbial resistance to this important class of antibiotics.
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###### 

Induction treatment of WK-ALL-2000 protocol.[@b14-jbm-4-001]

  Medicine                          Schedule of administration
  --------------------------------- -------------------------------------------------------------------------
  Methotrexate, ith                 Days 1, 15, 42
  Dexamethasone 6 mg/m^2^, po       Days 1--42
  Vincristine 1.5 mg/m^2^, iv       Days 8, 15, 22, 29, 36
  L-asparaginase 6.000 U/m^2^, iv   Days 8, 15 (standard-risk patients) or Days 29, 36 (high-risk patients)
  Daunorubicin 30 mg/m^2^, iv       Day 8 (high-risk patients only)

**Notes:** The dose of ith methotrexate was adjusted to age: \<1 year = 6 mg; 1--2 years = 8 mg; 2--3 years = 10 mg; ≥ 3 years = 12 mg. The dose of oral dexamethasone was tapered-on during the first week when the initial WBC count was \>20 × 10^9^/L and tapered-off during the sixth week in all patients. Bone marrow aspirations were done on day 0 for diagnosis and at the end of induction treatment to determine remission achievement.

**Abbreviations:** ith, intrathecal; po, per oral; iv, intravenous; WK-ALL-2000, Wijaya Kusuma acute lymphoblastic leukemia protocol.

###### 

Characteristics of patients

  Characteristics                                                                                    Placebo   Ciprofloxacin   Total   *P*-value                
  -------------------------------------------------------------------------------------------------- --------- --------------- ------- ----------- ----- ------ ------
  Total patients                                                                                     52        47.3            58      52.7        110   100    
  Sex                                                                                                                                                           
   Male                                                                                              34        65.4            37      60.3        69    62.7   0.86
   Female                                                                                            18        34.6            21      39.7        41    37.3   
  Age group (years)                                                                                                                                             
   1--9                                                                                              40        76.9            49      84.5        89    80.9   0.31
   10--14                                                                                            12        23.1            9       15.5        21    19.1   
  WBC at diagnosis (×10^9^/L)                                                                                                                                   
   \<50                                                                                              37        71.2            43      74.1        80    72.7   0.73
   ≥50                                                                                               15        28.8            15      25.9        30    27.3   
  Risk group                                                                                                                                                    
   Standard risk                                                                                     27        51.9            32      55.2        59    53.6   0.73
   High risk                                                                                         25        48.1            26      44.8        51    46.4   
  Nutritional status                                                                                                                                            
   Well-nourished                                                                                    29        55.8            44      75.9        73    66.4   0.03
   Undernourished                                                                                    23        44.2            14      24.1        37    33.6   
  Day 8 absolute peripheral lymphoblasts count (×10^9^/L)[a](#tfn4-jbm-4-001){ref-type="table-fn"}                                                              
   \<1                                                                                               40        80.0            44      80.0        84    80.0   1.00
   ≥1                                                                                                10        20.0            11      20.0        21    20.0   

**Note:**

Data were not available in five patients due to death or abandonment of treatment before measurement (n = 3 in ciprofloxacin group, n = 2 in placebo group).

**Abbreviation:** WBC, white blood cell.

###### 

Outcomes during induction treatment

  Outcomes              Placebo   Ciprofloxacin   Total   OR     95% CI   *P*-value                                                                 
  --------------------- --------- --------------- ------- ------ -------- ----------- ----------------------------------------------- ------------- ---------------------------------------------------
  Total patients        52        47.3            58      52.7   110      100                                                                       
  Induction outcome                                                                                                                                 
   Complete remission   39        75.0            40      69.0   79       71.8                                                                      
   Induction failures   13        25.0            18      31.0   31       28.2        1.35[a](#tfn7-jbm-4-001){ref-type="table-fn"}   0.58--3.12    0.48[\#](#tfn9-jbm-4-001){ref-type="table-fn"}
    Death               3         5.8             11      18.9   14       12.8        3.57[a](#tfn7-jbm-4-001){ref-type="table-fn"}   0.92--13.80   0.05[\#](#tfn9-jbm-4-001){ref-type="table-fn"}
    Abandonment         7         13.5            3       5.2    10       9.0         0.42[a](#tfn7-jbm-4-001){ref-type="table-fn"}   0.10--1.73    0.32[\#\#](#tfn10-jbm-4-001){ref-type="table-fn"}
    Resistant disease   3         5.8             4       6.9    7        6.4         1.3[a](#tfn7-jbm-4-001){ref-type="table-fn"}    0.27--6.19    1.00[\#\#](#tfn10-jbm-4-001){ref-type="table-fn"}
  Fever \> 38.5°C                                                                                                                                   
   Never                35        67.3            29      50.0   64       58.2                                                                      
   Ever                 17        32.7            29      50.0   46       41.8        2.06[b](#tfn8-jbm-4-001){ref-type="table-fn"}   0.95--4.47    0.07[\#](#tfn9-jbm-4-001){ref-type="table-fn"}
  Clinical sepsis                                                                                                                                   
   Never                32        61.5            29      50.0   61       55.5                                                                      
   Ever                 20        38.5            29      50.0   49       44.5        1.60[b](#tfn8-jbm-4-001){ref-type="table-fn"}   0.75--3.42    0.22[\#](#tfn9-jbm-4-001){ref-type="table-fn"}

**Notes:**

ORs for any induction failure and specific induction failures (CR is taken as the reference outcome category);

ORs for event of fever and clinical sepsis (Never is taken as the reference outcome category);

Chi-square test;

Fisher's exact test.

**Abbreviations:** OR, odds ratio (ciprofloxacin group relative to placebo group); CI, confidence interval.

###### 

Cause of death during induction treatment

  Causes of death           Placebo   Ciprofloxacin   Total               
  ------------------------- --------- --------------- ------- ------ ---- ------
  Total patients            3         11.4            11      78.6   14   100
  Sepsis                    3         5.8             2       3.4    5    35.7
  Varicella                 0         0               1       1.7    1    7.1
  Intracranial hemorrhage   0         0               2       3.4    2    14.2
  DIC                       0         0               1       1.7    1    7.1
  MODS                      0         0               1       1.7    1    7.1
  Hypovolemic shock         0         0               1       1.7    1    7.1
  Transfusion reaction      0         0               1       1.7    1    7.1
  No data or died at home   0         0               2       3.4    2    14.2

**Abbreviations:** DIC, disseminated intravascular coagulation; MODS, multiple organ dysfunction syndrome.

###### 

Adverse events during induction treatment

  Events           Placebo   Ciprofloxacin   Total                
  ---------------- --------- --------------- ------- ------ ----- ------
  Total patients   52        47.3            58      52.7   110   100
  Nausea           8         15.4            3       5.2    11    10.0
  Vomiting         7         13.5            6       10.3   13    11.8
  Diarrhea         2         3.8             4       6.9    6     5.5
  Neuritis         7         13.5            5       8.6    12    11.0

###### 

Presentation at diagnosis and clinical outcome

  Patient   Random   Sex   Age (years, months)   WBC count (/μl)   Risk group   Nutritional state   Day 8 response (/μl)   Induction outcome   Cause of death                           Fever   Sepsis
  --------- -------- ----- --------------------- ----------------- ------------ ------------------- ---------------------- ------------------- ---------------------------------------- ------- --------
  1         Cip      M     7, 02                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Never
  2         Pcb      F     5, 05                 ≥50,000           HR           Well                \<1000                 CR                                                           Never   Never
  3         Pcb      F     5, 01                 \<50,000          SR           Well                ≥1000                  CR                                                           Never   Never
  4         Cip      F     3, 04                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Ever
  5         Cip      M     10, 00                ≥50,000           HR           Well                \<1000                 CR                                                           Never   Never
  6         Cip      F     10, 00                ≥50,000           HR           Under               \<1000                 RD                                                           Ever    Never
  7         Pcb      M     1, 00                 ≥50,000           HR           Under               ≥1000                  CR                                                           Ever    Ever
  8         Cip      M     4, 01                 ≥50,000           HR           Well                ≥1000                  Death               Disseminated intravascular coagulation   Ever    Never
  9         Pcb      M     14, 01                ≥50,000           HR           Under               ≥1000                  Death               Sepsis                                   Ever    Ever
  10        Cip      M     4, 04                 ≥50,000           HR           Well                \<1000                 Death               Sepsis                                   Ever    Ever
  11        Pcb      M     7, 03                 ≥50,000           HR           Under               \<1000                 Death               Sepsis                                   Never   Never
  12        Cip      F     5, 11                 ≥50,000           HR           Well                ≥1000                  CR                                                           Ever    Ever
  13        Cip      M     2, 07                 \<50,000          SR           Under               \<1000                 CR                                                           Ever    Ever
  14        Cip      F     14, 01                ≥50,000           HR           Well                ≥1000                  CR                                                           Ever    Never
  15        Cip      M     8, 06                 \<50,000          SR           Under               \<1000                 CR                                                           Ever    Ever
  16        Cip      F     1, 08                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Ever
  17        Pcb      M     2, 06                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Ever
  18        Pcb      M     13, 00                \<50,000          HR           Under               \<1000                 CR                                                           Never   Ever
  19        Cip      M     1, 10                 \<50,000          HR           Well                \<1000                 CR                                                           Never   Ever
  20        Pcb      M     2, 05                 ≥50,000           HR           Well                \<1000                 CR                                                           Never   Never
  21        Pcb      M     13, 01                \<50,000          HR           Well                \<1000                 CR                                                           Never   Never
  22        Pcb      F     9, 09                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Never
  23        Pcb      F     6, 06                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Ever
  24        Cip      F     6, 07                 \<50,000          SR           Under               \<1000                 CR                                                           Never   Never
  25        Cip      M     2, 09                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  26        Pcb      M     8, 01                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  27        Cip      M     7, 05                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Ever
  28        Cip      M     1, 08                 ≥50,000           HR           Well                \<1000                 CR                                                           Ever    Ever
  29        Pcb      M     6, 03                 \<50,000          SR           Under               \<1000                 CR                                                           Never   Never
  30        Cip      M     13, 00                ≥50,000           HR           Well                ≥1000                  RD                                                           Ever    Ever
  31        Pcb      M     2, 01                 \<50,000          SR           Under               \<1000                 CR                                                           Ever    Ever
  32        Pcb      F     14, 00                ≥50,000           HR           Under               ≥1000                  RD                                                           Never   Never
  33        Cip      F     1, 06                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Ever
  34        Pcb      M     6, 06                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Ever
  35        Cip      M     3, 03                 \<50,000          SR           Under               \<1000                 CR                                                           Ever    Ever
  36        Pcb      F     7, 08                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  37        Pcb      M     3, 03                 \<50,000          SR           Under               \<1000                 Abn                                                          Never   Ever
  38        Pcb      F     2, 11                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  39        Cip      M     5, 01                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Never
  40        Cip      M     3, 02                 ≥50,000           HR           Well                \<1000                 CR                                                           Ever    Never
  41        Pcb      M     4, 03                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Ever
  42        Pcb      M     6, 07                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  43        Cip      F     4, 00                 \<50,000          SR           Under               \<1000                 CR                                                           Ever    Ever
  44        Cip      M     14, 00                ≥50,000           HR           Under               ≥1000                  Abn                                                          Never   Ever
  45        Pcb      M     4, 01                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  46        Pcb      M     1, 03                 \<50,000          SR           Well                \<1000                 Abn                                                          Ever    Ever
  47        Pcb      F     7, 07                 \<50,000          SR           Well                \<1000                 Abn                                                          Never   Never
  48        Pcb      M     12, 01                \<50,000          HR           Under               No data                Abn                                                          Never   Never
  49        Pcb      M     4, 02                 \<50,000          SR           Under               \<1000                 CR                                                           Ever    Ever
  50        Cip      F     6, 05                 \<50,000          HR           Well                \<1000                 CR                                                           Ever    Ever
  51        Cip      M     3, 04                 \<50,000          HR           Well                \<1000                 CR                                                           Never   Never
  52        Cip      F     11, 00                \<50,000          HR           Under               \<1000                 Death               Sepsis                                   Ever    Ever
  53        Pcb      M     4, 08                 ≥50,000           HR           Well                No data                Death               Sepsis                                   Ever    Ever
  54        Cip      M     2, 05                 \<50,000          HR           Under               No data                Death               Multiple organs dysfunction              Ever    Ever
  55        Pcb      M     5, 02                 \<50,000          SR           Under               \<1000                 CR                                                           Ever    Never
  56        Cip      F     8, 01                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  57        Cip      M     2, 08                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Never
  58        Cip      M     4, 09                 \<50,000          HR           Well                \<1000                 CR                                                           Ever    Ever
  59        Cip      M     9, 03                 \<50,000          SR           Under               \<1000                 RD                                                           Ever    Never
  60        Cip      F     9, 07                 \<50,000          SR           Well                \<1000                 Death               Hypovolemic shock                        Ever    Ever
  61        Cip      M     2, 09                 \<50,000          SR           Well                No data                Death               Intracranial hemorrhage                  Ever    Ever
  62        Pcb      F     5, 03                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  63        Pcb      F     5, 07                 ≥50,000           HR           Under               \<1000                 CR                                                           Never   Ever
  64        Cip      M     3, 04                 \<50,000          SR           Well                ≥1000                  CR                                                           Never   Never
  65        Cip      M     8, 09                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Ever
  66        Cip      F     4, 08                 \<50,000          SR           Under               \<1000                 CR                                                           Never   Never
  67        Pcb      F     2, 09                 \<50,000          SR           Well                \<1000                 RD                                                           Ever    Ever
  68        Cip      F     2, 07                 \<50,000          SR           Well                ≥1000                  Death               No data                                  Never   Ever
  69        Pcb      F     6, 09                 \<50,000          SR           Under               ≥1000                  CR                                                           Never   Never
  70        Cip      M     10, 00                ≥50,000           HR           Well                \<1000                 CR                                                           Never   Never
  71        Pcb      M     8, 01                 ≥50,000           HR           Under               ≥1000                  Abn                                                          Ever    Ever
  72        Cip      M     3, 08                 \<50,000          SR           Well                ≥1000                  CR                                                           Ever    Ever
  73        Cip      M     5, 09                 \<50,000          HR           Under               \<1000                 CR                                                           Never   Ever
  74        Cip      M     4, 01                 \<50,000          SR           Well                No data                Abn                                                          Never   Never
  75        Cip      F     13, 00                \<50,000          HR           Well                ≥1000                  Death               No data                                  Never   Never
  76        Cip      M     2, 03                 ≥50,000           HR           Well                ≥1000                  RD                                                           Ever    Ever
  77        Pcb      M     12, 01                \<50,000          HR           Well                \<1000                 CR                                                           Never   Never
  78        Pcb      M     8, 07                 \<50,000          SR           Under               \<1000                 CR                                                           Never   Never
  79        Cip      F     4, 05                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Never
  80        Pcb      M     2, 01                 ≥50,000           HR           Well                ≥1000                  CR                                                           Never   Never
  81        Pcb      M     7, 05                 ≥50,000           HR           Under               ≥1000                  Abn                                                          Never   Ever
  82        Pcb      M     11, 01                \<50,000          HR           Under               \<1000                 CR                                                           Never   Never
  83        Pcb      M     14, 00                ≥50,000           HR           Well                ≥1000                  CR                                                           Never   Never
  84        Cip      M     10, 00                \<50,000          HR           Well                \<1000                 Death               Varicella                                Never   Never
  85        Cip      M     3, 08                 \<50,000          HR           Well                \<1000                 CR                                                           Never   Never
  86        Pcb      M     12, 00                \<50,000          HR           Under               \<1000                 CR                                                           Ever    Ever
  87        Cip      F     2, 00                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  88        Cip      M     5, 09                 ≥50,000           HR           Well                \<1000                 Death               Transfusion reaction                     Never   Never
  89        Cip      M     4, 04                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  90        Pcb      M     14, 01                ≥50,000           HR           Under               \<1000                 CR                                                           Ever    Never
  91        Pcb      M     5, 05                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  92        Pcb      M     2, 00                 \<50,000          SR           Well                \<1000                 RD                                                           Never   Never
  93        Cip      M     3, 00                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Ever
  94        Pcb      F     5, 04                 \<50,000          SR           Under               \<1000                 Abn                                                          Never   Never
  95        Cip      M     3, 03                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  96        Pcb      F     2, 02                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  97        Pcb      M     1, 01                 \<50,000          HR           Well                \<1000                 CR                                                           Never   Never
  98        Pcb      F     8, 02                 ≥50,000           HR           Under               \<1000                 CR                                                           Never   Ever
  99        Cip      F     6, 05                 ≥50,000           HR           Well                \<1000                 Abn                                                          Never   Never
  100       Cip      M     4, 09                 ≥50,000           HR           Well                \<1000                 Death               Intracranial hemorrhage                  Never   Ever
  101       Pcb      F     4, 00                 ≥50,000           HR           Under               \<1000                 CR                                                           Never   Ever
  102       Pcb      F     3, 06                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Ever
  103       Cip      M     3, 01                 \<50,000          HR           Under               ≥1000                  CR                                                           Never   Never
  104       Pcb      F     14, 00                \<50,000          HR           Well                \<1000                 CR                                                           Ever    Never
  105       Cip      M     3, 11                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Ever
  106       Pcb      M     8, 04                 \<50,000          HR           Well                ≥1000                  CR                                                           Never   Never
  107       Pcb      M     12, 01                \<50,000          HR           Under               \<1000                 CR                                                           Never   Never
  108       Cip      M     3, 06                 \<50,000          SR           Under               \<1000                 CR                                                           Ever    Never
  109       Cip      F     5, 06                 \<50,000          SR           Well                \<1000                 CR                                                           Never   Never
  110       Cip      F     5, 03                 \<50,000          SR           Well                \<1000                 CR                                                           Ever    Ever

**Abbreviations:** Cip, ciprofloxacin; Pcb, placebo; F, female; M, male; SR, standard risk; HR, high risk; Well, well-nourished; Under, undernourished; CR, complete remission; RD, resistant disease; Abn, abandonment to treatment.
